METABIOMED (059210) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, METABIOMED (059210) reported revenue of 103.0 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025103.0 billion KRW21.4 billion KRW10.8 billion KRW[source]
202494.0 billion KRW17.2 billion KRW22.3 billion KRW[source]
202383.1 billion KRW10.7 billion KRW9.8 billion KRW[source]
202268.9 billion KRW5.3 billion KRW3.6 billion KRW[source]
202158.8 billion KRW4.9 billion KRW9.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025183.7 billion KRW58.0 billion KRW125.7 billion KRW[source]
2024171.1 billion KRW77.0 billion KRW94.2 billion KRW[source]
2023123.7 billion KRW52.9 billion KRW70.8 billion KRW[source]
2022114.0 billion KRW52.5 billion KRW61.6 billion KRW[source]
202197.3 billion KRW38.4 billion KRW59.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice